Mission Bay Capital β Full Portfolio
31 tracked investments Β· listed companies and verified rows first
Alector develops therapies targeting neurodegenerative diseases including Alzheimer's, frontotemporal dementia, and Parkinson's disease through protein removal, replacement, and immune cell restoration.
AI & Machine LearningBiotechHealthtechLongevityMedical DevicesSan Francisco, US
Arnon Rosenthal(Ph.D.)Tillman Gerngross(Director)
BoardCarl Gordon(Director)Terry McGuire(Director)in
Co-investorsForesite CapitalMission BiocapitalMRL Ventures FundSV Health InvestorsPolaris Partners
Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform.
BiotechMedical DevicesBerkeley, US
Jennifer Doudna(Co-founder)Rachel Haurwitz(President and Chief Executive Officer, Co-founder)Martin Jinek(Co-founder)Andrew May(Executive Officer)
BoardJenny Rooke(Director)Robert Weisskoff(Director)in
Co-investorsAliment CapitalAvego BioScience CapitalF-Prime Capital PartnersIA Seed VenturesMission BiocapitalPontifax AgTech+2 more
Alessa Therapeutics develops a proprietary drug-delivery platform for sustained and localized release of therapies to treat early-stage prostate cancer.
BiotechHealthtechMedical DevicesSan Carlos, US
Pamela Munster(Founder, Chief Scientific Advisor and Director)Cam Gallagher(Executive Officer, Director)inJohn Maroney(Executive Officer, Director)
BoardZachary Collins(Executive Officer)inSteve Tregay(Director)inAnnie Mitsak(Director)in
Co-investorsCure VenturesMission Biocapital
Avvio Medical develops Microbubble SonoLithotripsy, a minimally invasive outpatient procedure that uses low-intensity ultrasound to break down ureteral stones without requiring general anesthesia or stents.
Deep TechHealthtechMedical DevicesSan Francisco, US
Co-investorsBaruch Future VenturesBerkeley CatalystMission Biocapital
Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.
BiotechHealthtechMedical DevicesSan Francisco, US
Ivana Djuretic(Founder)inAndy Yeung(Founder)in
Co-investorsEmles Venture PartnersGoAhead VenturesMission BiocapitalRA CapitalY CombinatorThird Rock Ventures
BiotechRedwood City, US
William Robinson(Director)Lawrence Steinman(Director)Tito Serafini(Executive Officer, Director)
BoardBrian Atwood(Director)Franklin Berger(Director)
Co-investorsAisling CapitalEcoR1 CapitalMission Biocapital
Co-investorsMission Biocapital
Bolt Threads was a manufacturer of biomaterials for personal care formulations.
BiotechNew MaterialsFoxboro, US
Ethan Mirsky(Executive Officer)David Breslauer(Executive Officer, Director)Daniel Widmaier(Executive Officer, Director)Paul Koontz(Director)
BoardJerry Fiddler(Director)Steven Vassallo(Director)in
Co-investorsMission Biocapital8VCBaillie GiffordEast West Capital LimitedFidelity InvestmentsFoundation Capital+2 more
Co-investorsMission BiocapitalLongwood Fund
BiotechLafayette, US
Peter Emtage(Executive Officer)Greg Giotta(Executive Officer)Brian Atwood(Executive Officer, Director, Promoter)
BoardFred Cohen(Executive Officer, Director, Promoter)Brook Byers(Director)inArie Belldegrun(Director)
Co-investorsKleiner PerkinsOUP (Osage University Partners)
HealthtechHayward, US
GUY DIPIERRO(Director)ALAN LEVY, PH.D.(Executive Officer, Director)ANTHONY RIMAC(Executive Officer)ALAN LEVY(Executive Officer, Director)
BoardELIZABETH ROCKETT(Director)WENDE HUTTON(Director)in
Co-investorsEmergent Medical Partners, LLPFountain Healthcare PartnersKaiser Permanente VenturesCanaan Partners
Circle Pharma develops cancer treatments using macrocycle therapies designed to reduce side effects compared to conventional therapies.
BiotechDigital HealthHealthtechMedical DevicesSouth San Francisco, US
Matthew P. Jacobson(Co-founder)Scott R. Lokey(Director)Matthew Jacobson(Director)David J. Earp(President & CEO)Paul Park(Executive Officer)
BoardThilo Schroeder(Director)in
Co-investorsBerkeley CatalystLifeforce CapitalMission BiocapitalNextech InvestPandect BioventuresThe Column Group+1 more
Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
BiotechHealthtechMedical DevicesFoster City, US
Nenad Tomasevic(Executive Officer, Director)
BoardIvan Trifunovich(Director)John Wesley(Director)
Co-investors8VCAisling CapitalMission BiocapitalOlive Tree CapitalTaiho Ventures, LLCHBM Healthcare Investments+1 more
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Co-investorsAstellas Venture Management LLCMission BiocapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture PartnersSofinnova Ventures
Epiodyne develops small-molecule opioids designed to optimize therapeutic outcomes, with initial focus on safer pain relief and improved opioid use disorder treatment with reduced addiction and respiratory depression risk.
BiotechHealthtechMedical DevicesSan Francisco, US
Brian Shoichet(Director)Douglas Crawford, Ph.D.(CEO)Don Gehlert, Ph.D.(Head of Biology)
BoardDouglas Crawford(Executive Officer, Director)in
Co-investorsMenlo VenturesMission BiocapitalKleiner Perkins
Cell Microsystems develops laboratory instruments and platforms for cell engineering, culture, and analysis.
BiotechDeep TechHardware
Co-investorsClaremont Creek VenturesMission BiocapitalSignet Healthcare Partners
Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.
Biotech
Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)
Co-investorsAdvent Life SciencesMission BiocapitalRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures
Invenio develops rapid on-site tissue imaging systems combined with AI to improve cancer patient care.
AI & Machine LearningBiotechDeep TechMedical DevicesSanta Clara, US
Jay Trautman(President & CEO, Co-Founder)Chris Freudiger(Chief Technology Officer, Co-Founder)Christian Freudiger(Director)Xiaoliang Xie(Director)
BoardDoug Crawford(Director)in
Co-investorsBerkeley CatalystMission Biocapital
Kit provides email marketing and commerce tools for creators and independent businesses to reach audiences and monetize their work through newsletters and storefronts.
Creator EconomyMarketing TechSaaS
Nathan Barry(Founder + CEO)
Co-investorsAUTHENTIC VENTURESBrighter CapitalExpaMission BiocapitalWAGMI VenturesOceans Ventures+1 more
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)Lucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONDecheng CapitalForesite CapitalMayfield Fund+9 more
MPM Capital is a venture capital and life sciences investment firm that backs companies in biotech, therapeutics, and healthcare innovation, with a focus on translating scientific research into transformative medicines and treating severe diseases.
Biotech
Ansbert Gadicke(Chairman)Chris Bardon(Managing Partner)
Berkeley, US
Co-investorsAutodesk FoundationAVA AngelsBerkeley SkyDeck FundCRV (Charles River Ventures)Melbourne Accelerator Program (MAP)Moonhill Capital+1 more
Nitrase Therapeutics develops medicines based on nitrases, a class of enzymes it discovered that are involved in a range of diseases.
Biotech
Co-investorsMission BiocapitalSofinnova PartnersDementia Discovery Fund
HealthtechSan Francisco, US
Matthew F. Krummel, Ph.D.(Director)Steven P. James(Executive Officer, Director, Promoter)Leon Chen, Ph.D.(Director)Carol Gallagher(Director)Joshua Resnick, M.D.(Director)
BoardMichael Powell(Director)
Co-investorsMission BiocapitalOUP (Osage University Partners)Sofinnova VenturesSofinnova Venture Partners
BiotechSouth San Francisco, US
MARTIN BABLER(Executive Officer, Director)
BoardPETER THOMPSON(Director)SRINIVAS AKKARAJU(Director)MICHAEL DYBBS(Director)inSIMEON GEORGE(Director)LEWIS J. SHUSTER(Director)
Co-investorsAccess BiotechnologyMission BiocapitalSofinnova VenturesNew Leaf Venture PartnersOrbiMedSamsara BioCapital
Vedere Bio develops optogenetics-based gene therapies for inherited retinal diseases (IRDs) and geographic atrophy (GA), using proprietary AAV vectors for intravitreal administration to restore vision in visually impaired patients globally.
BiotechDeep TechMedical DevicesCambridge, US
Co-investorsMission Biocapital
Co-investorsPfizer Venture Investments
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.